Atlas Trials

Study to Evaluate the Efficacy and Safety Of Intravesical Nanoxel®M In BCG Refractory NMIBC

Clinical trial NCT02982395 · TERMINATED

Trial details

NCT number
NCT02982395
Sponsor
Samyang Biopharmaceuticals Corporation
Status
TERMINATED
Phase
Phase 3
Study type
INTERVENTIONAL
Non Muscle Invasive Bladder Cancer
Start date
2017-01-01
Primary completion
2018-08-01
Enrollment
36

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.